Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

5.040 +0.040 (+0.80%)
Streaming Delayed Price Updated: 9:56 AM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗
Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets. 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Top movers in Tuesday's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026. 
Via Benzinga
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark ↗
Via Stocktwits
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
This Trex Company Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Reports Q3 2025 Earnings Miss on Revenue, Beat on EPS ↗
Vanda Pharma's Q3 2025 results show a revenue miss but a smaller-than-expected loss. The stock fell as strong Fanapt sales growth was offset by investor focus on the top-line shortfall. 
Via Chartmill
Topics Earnings
News headline image
A Glimpse of Vanda Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda Pharmaceuticals. 
Via Benzinga
News headline image
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas. 
Via Benzinga
News headline image
Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals” ↗
The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety. 
Via Stocktwits
Topics Retirement
News headline image
Vanda (VNDA) Q2 Revenue Rises 4% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate ↗
FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process. 
Via Benzinga
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst ↗
HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology. 
Via Benzinga
News headline image
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today ↗
A regulator's decision drained the market's enthusiasm for the company. 
Via The Motley Fool
News headline image
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies ↗
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets... 
Via Benzinga
News headline image
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
News headline image
What's Going On With Vanda Pharmaceuticals Shares Today? ↗
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.